Acrivastine

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking histamine H1 receptors.

Acrivastine
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa682619
Pregnancy
category
  • US: B (No risk in non-human studies)
    Routes of
    administration    		oral
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Elimination half-life1.5 hours
    ExcretionRenal
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.110.306
    Chemical and physical data
    FormulaC22H24N2O2
    Molar mass348.438 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.

    In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

    Unlike cetirizine or loratadine, for which the standard dose is one tablet per day, a single acrivastine tablet may be taken up to three times a day.[2] It is not to be taken by people over the age of 65, pregnant women, or people with compromised liver or kidney function.

    References
    1. SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
    2. "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Archived from the original on 27 September 2012. Retrieved 4 July 2014.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.